G Prasad
University of Agriculture, Faisalabad
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by G Prasad.
Biomedicine & Pharmacotherapy | 2018
Minakshi Prasad; Upendra P. Lambe; Basanti Brar; Ikbal Shah; J. Manimegalai; Koushlesh Ranjan; Rekha Rao; Sunil Kumar; Sheefali Mahant; Sandip Kumar Khurana; Hafiz M.N. Iqbal; Kuldeep Dhama; Jyoti Misri; G Prasad
In recent years nanotechnology has revolutionized the healthcare strategies and envisioned to have a tremendous impact to offer better health facilities. In this context, medical nanotechnology involves design, fabrication, regulation, and application of therapeutic drugs and devices having a size in nano-range (1-100u2009nm). Owing to the revolutionary implications in drug delivery and gene therapy, nanotherapeutics has gained increasing research interest in the current medical sector of the modern world. The areas which anticipate benefits from nano-based drug delivery systems are cancer, diabetes, infectious diseases, neurodegenerative diseases, blood disorders and orthopedic problems. The development of nanotherapeutics with multi-functionalities has considerable potential to fill the lacunae existing in the present therapeutic domain. Nanomedicines in the field of cancer management have enhanced permeability and retention of drugs thereby effectively targeting the affected tissues. Polymeric conjugates of asparaginase, polymeric micelles of paclitaxel have been recmended for various types of cancer treatment .The advancement of nano therapeutics and diagnostics can provide the improved effectiveness of the drug with less or no toxicity concerns. Similarly, diagnostic imaging is having potential future applications with newer imaging elements at nano level. The newly emerging field of nanorobotics can provide new directions in the field of healthcare. In this article, an attempt has been made to highlight the novel nanotherapeutic potentialities of polymeric nanoparticles, nanoemulsion, solid lipid nanoparticle, nanostructured lipid carriers, dendrimers, nanocapsules and nanosponges based approaches. The useful applications of these nano-medicines in the field of cancer, nutrition, and health have been discussed in details. Regulatory and safety concerns along with the commercial status of nanosystems have also been presented. In summary, a successful translation of emerging nanotherapeutics into commercial products may lead to an expansion of biomedical science. Towards the end of the review, future perspectives of this important field have been introduced briefly.
Indian Journal of Virology | 2011
Y. S. Malik; K. M. Chandrashekar; Kuldeep Sharma; Minakshi Prasad; G Prasad
Human group B rotavirus (HuGBR) was first described as the causative agent of severe gastroenteritis, affecting millions of people in China during 1982–1983. In spite of serological evidences for the presence of HuGBR in many countries of the world, the virus has only been detected from China, Bangladesh and some parts of India. The present study describes a HuGBR (designated as MP-1 isolate) which was confirmed in an adult patient suffering from gastroenteritis in 2008 in Madhya Pradesh, central India. The RNA electrophoresis in polyacrylamide gel (RNA-PAGE) and NSP2 gene based RT–PCR assays and later sequencing was used to confirm the isolate. The nucleotide and deduced amino acid sequences of this HuGBR (MP-1) isolate were analyzed and their relationship with corresponding gene of other Indian, Bangladeshi and Chinese HuGBR and animal group B rotaviruses (AnGBR) was determined. The isolate showed a typical RNA banding pattern of 4:2:2:3 in RNA-PAGE which was indicative of group B rotaviruses (GBR). The sequence comparison of MP-1 isolate with NSP2 gene revealed that MP-1 isolate had 98.6 and 97.7% nucleotide sequence homology and 93.8% amino acid similarity with Bang373 and CAL-1 strains, respectively. The nucleotide and amino acid sequence similarity of MP-1 isolate with one of the Chinese ADRV (WH-1) strain was 92.8 and 92.5%, respectively. While sequence homology with another Chinese strain ADRV (J19) was considerably lower (45.6 and 48.3%, respectively). The percent identity with AnGBRs (porcine and murine) was also lower at nucleotide and amino acid level (66 to 80%). The phylogenetic analysis suggested that MP-1 isolate is closer to Bangladeshi (Bang373) as compared to Indian strain (CAL-1). Our findings indicated that MP-1 isolate might have originated from a common ancestral HuGBR virus but distinct from AnGBR lineage. Occurrence of GBR in other parts of India warrants further epidemiological and molecular studies to develop effective control strategies for GBR infection in adults as well as children.
Indian Journal of Animal Sciences | 2012
Jitendra K. Biswal; Aniket Sanyal; Luis L. Rodriguez; Saravanan Subramaniam; Jonathan Arzt; Gaurav K. Sharma; Jef Hammond; Satya Parida; Jajati K. Mohapatra; Basavaraj S. Mathapati; Bana B. Dash; Rajeev Ranjan; Manoranjan Rout; Ramamurthy Venketaramanan; Jyoti Misri; Lal Krishna; G Prasad; K. M. L. Pathak; Bramhadev Pattnaik
Indian Journal of Animal Sciences | 2002
S K Mishra; G Prasad; Minakshi Minakshi; Yashpal Singh Malik; N K Kmahajan; V Praksh
Indian Journal of Animal Sciences | 2008
A L Kusumakar; Savita; Yashpal Singh Malik; Minakshi; G Prasad
Indian Journal of Animal Sciences | 2009
Minakshi; G Prasad; Y P Grover
Indian Journal of Animal Sciences | 2011
Satish Satish; Ashwani Kumar; Yasmeen Singh; Minakshi Minakshi; G Prasad
Indian Journal of Biotechnology | 2010
B. N. Manjunatha; Minakshi Prasad; Sushila Maan; G Prasad
Indian Journal of Animal Sciences | 2000
Yashpal Singh Malik; Minakshi; Sushila Maan; G Prasad
Current Biomarkers | 2018
Minakshi Prasad; Koushlesh Ranjan; Basanti Brar; J. Manimegalai; G Prasad
Collaboration
Dive into the G Prasad's collaboration.
Lala Lajpat Rai University of Veterinary and Animal Sciences
View shared research outputsLala Lajpat Rai University of Veterinary and Animal Sciences
View shared research outputs